Literature DB >> 25931438

Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China.

Y H Che1, V Chongsuvivatwong2, L Li3, H Sriplung2, Y Y Wang4, J You5, S J Ma6, Y Yan7, R Y Zhang6, T Shen6, H M Chen6, S F Rao6, X L Zhang6.   

Abstract

OBJECTIVE: To investigate the financial burden of patients who had various stages of hepatitis B virus-related diseases and the level of alleviation from financial burden by health insurance schemes in Yunnan province of China. STUDY
DESIGN: A cross-sectional survey.
METHODS: Patients' information was consecutively recorded at the First Affiliated Hospital of Kunming Medical University, from December 2012 to June 2013. Consecutive cases of hepatitis B virus (HBV) (520), compensated cirrhosis (91), decompensated cirrhosis (198) and hepatocellular carcinoma (HCC) (131) were recruited from the outpatient and inpatient departments. The total direct costs, hospital charge, outpatient costs, hospitalization fees being reimbursed and household catastrophic health expenditure were estimated for each disease group.
RESULTS: The average annual direct costs for each disease group were 19,496 RMB for HBV, 28,466 RMB in compensated cirrhosis, 46,061 RMB for decompensated cirrhosis, and 33,044 RMB for HCC patients. Catastrophic health expenditure occurred in all four groups. Health insurance reimbursement released the financial burden incurred by medical expenses of patients under a high level of household economic status. Public health insurance schemes helped the patients to various extents.
CONCLUSIONS: Among these patient groups, direct costs represent a significant economic burden. Health expenditure and financing systems must be considered to prevent the increase of household catastrophe, particularly among the poor.
Copyright © 2015 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Catastrophic; Costs; Disease stage; Hepatitis B

Mesh:

Year:  2015        PMID: 25931438     DOI: 10.1016/j.puhe.2015.03.015

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  6 in total

1.  Epidermal growth factor receptor transactivation is involved in the induction of human hepatoma SMMC7721 cell proliferation by insufficient radiofrequency ablation.

Authors:  Hongliang Dai; Guizhi Jia; Hongxin Wang; Jingming Yang; Hua Jiang; Minghui Chu
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

2.  Economic Burden and Quality of Life of Hepatocellular Carcinoma in Greater China: A Systematic Review.

Authors:  Huimin Zou; Meng Li; Qing Lei; Zejun Luo; Yan Xue; Dongning Yao; Yunfeng Lai; Carolina Oi Lam Ung; Hao Hu
Journal:  Front Public Health       Date:  2022-04-21

Review 3.  Cost Assessment of Hepatitis B Virus-related Hepatitis in Bangladesh.

Authors:  Mamun Al Mahtab; Muntasir Chaudhury; Mohammad H Uddin; Sheikh M Noor-E Alam; Mohammad A Rahim; Mohammad A Alam; Ahmed L Moben; Faiz A Khondaker; Mohammad Fi Choudhury; Mohammad Ja Sarkar; Provat K Poddar; Syed A Foez; Sheikh Mf Akbar
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-12-01

4.  Comparison of ARIMA and GM(1,1) models for prediction of hepatitis B in China.

Authors:  Ya-Wen Wang; Zhong-Zhou Shen; Yu Jiang
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

5.  Social Determinants of Stigma and Discrimination in Vietnamese Patients with Chronic Hepatitis B.

Authors:  Thieu Van Le; Thuc Thi Minh Vu; Hue Thi Mai; Long Hoang Nguyen; Nu Thi Truong; Chi Linh Hoang; Son Hoang Nguyen; Cuong Tat Nguyen; Binh Cong Nguyen; Tung Hoang Tran; Bach Xuan Tran; Carl A Latkin; Cyrus S H Ho; Roger C M Ho
Journal:  Int J Environ Res Public Health       Date:  2019-01-31       Impact factor: 3.390

6.  The trend of direct medical costs and associated factors in patients with chronic hepatitis B in Guangzhou, China: an eight-year retrospective cohort study.

Authors:  Shuo Yang; Ge Chen; Yueping Li; Guanhai Li; Yingfang Liang; Feng Zhou; Shudong Zhou; Yi Yang; Weidong Jia; Yanhui Gao; Yue Chen
Journal:  BMC Med Inform Decis Mak       Date:  2021-07-30       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.